REPL

Replimune Group
REPL

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$719.22M
EV
$311.58M
Shares Outstanding
77.09M
Beta
0.62

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$21.88
P/E 2026E
-
P/Revenue 2026E
12.59x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Replimune Group, Inc.

gainify
REPL

Replimune Group, Inc.

REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune...

Sector

Healthcare

Industry

Biotechnology

CEO

Patel, Sushil

Employees

479

IPO Date

2018-07-20

Headquarters

500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts, 01801, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

COMPANY

Pricing

Dashboard

About Us

Contact Us

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.